Sign Up! | Tags | Domains | Statistics | Options | Advanced Search
|
Sign Up! | Tags | Domains | Statistics | Options | Advanced Search |
 |
Targanta-Cubist Rivalry Brews on FDA Review of Targanta Drugxconomy.com » Xconomy - 2 hours ago pharma, Life Sciences, Biotech Ryan McBride wrote: Targanta Therapeutics’ stock has made gains since an FDA advisory committee yesterday posted a favorable review of Targanta antibiotic oritavancin to treat certain … Also tagged: people, biotech, boston, life sciences, alan carr, boston blog main, national blog main, targanta therapeutics, cubist pharmaceuticals, mark leuchtenberger, oritavancin, michael bonney, needham and 38 company |
xconomy.com » Xconomy - Nov 16, 2008
Layoffs, Life Sciences, Drug Development Wade Roush wrote: Another day, another bundle of layoffs. Boston-based biofuels startup Mascoma is laying off between five and 10 employees, according to a report today in the …
Also tagged: energy, boston, economy, pharmaceuticals, drug development, layoffs, pain management, life sciences, cleantech, javelin, mascoma, boston blog main, national blog main, javelin pharmaceuticals, colin south
xconomy.com » Xconomy Life Sciences Feed - Nov 15, 2008
Layoffs, Life Sciences, Drug Development Wade Roush wrote: Another day, another bundle of layoffs. Boston-based biofuels startup Mascoma is laying off between five and 10 employees, according to a report today in the …
Also tagged: energy, boston, economy, pharmaceuticals, drug development, layoffs, pain management, life sciences, cleantech, javelin, mascoma, boston blog main, national blog main, javelin pharmaceuticals, colin south
xconomy.com » Xconomy Energy Feed - Nov 14, 2008
Layoffs, Life Sciences, Drug Development Wade Roush wrote: Another day, another bundle of layoffs. Boston-based biofuels startup Mascoma is laying off between five and 10 employees, out of a total staff of 20 …
Also tagged: energy, boston, economy, pharmaceuticals, drug development, layoffs, pain management, life sciences, cleantech, javelin, mascoma, boston blog main, national blog main, javelin pharmaceuticals, colin south
xconomy.com » Xconomy - Nov 14, 2008
Life Sciences, Biotech, Stem Cells Ryan McBride wrote: Drug giant Pfizer (NYSE:PFE) has announced the launch of Pfizer Regenerative Medicine, an independent research unit focused on discovering stem cell treatments …
Also tagged: biotech, boston, pfizer, stem cells, life sciences, boston briefs, research technology centre, pfizer regenerative medicine
xconomy.com » Xconomy Venture Capital Feed - Nov 6, 2008
Roundup, Life Sciences, deals Rebecca Zacks wrote: Last week brought an interesting mix of theory and practice about the impact of the current economic climate on life sciences. —There was a flurry of news related to …
Also tagged: drugs, people, roundup, vc, boston, deals, startups, genentech, dyax, bessemer venture partners, life sciences, genzyme, biogen idec, fred hutchinson cancer research center, cephalon, elan, tysabri, fred baron, boston blog main, national blog main, vertex pharmaceuticals, third rock ventures, acusphere, telaprevir, frazier healthcare ventures, fidelity biosciences, novartis option fund, alnara pharmaceuticals, azimuth opportunity, lauren silverman, bcm technologies, neuroventures capital, envivo pharmaceuticals, cogene ventures, ra capital management, peter kolchinsky, osiris therapeutics
 |
Justice Department Investigates Drugmakers' Marketingtruthout.org » Truthout - News - Nov 5, 2008 Trenton, New Jersey - Lawsuits against Merck & Co. and partner Schering-Plough Corp. related to their marketing of cholesterol drug Vytorin are piling up, and the U.S. Department of Justice has begun investigating … Also tagged: health, lawsuits, pharmaceutical, merck, department of justice, schering plough, drugmakers, vytorin |
xconomy.com » Xconomy Boston - Nov 5, 2008
Roundup, Life Sciences, deals Rebecca Zacks wrote: Last week brought an interesting mix of theory and practice about the impact of the current economic climate on life sciences. —There was a flurry of news related to …
Also tagged: drugs, people, roundup, vc, boston, deals, startups, genentech, dyax, bessemer venture partners, life sciences, genzyme, biogen idec, fred hutchinson cancer research center, cephalon, elan, tysabri, fred baron, boston blog main, national blog main, vertex pharmaceuticals, third rock ventures, acusphere, telaprevir, frazier healthcare ventures, fidelity biosciences, novartis option fund, alnara pharmaceuticals, azimuth opportunity, lauren silverman, bcm technologies, neuroventures capital, envivo pharmaceuticals, cogene ventures, ra capital management, peter kolchinsky, osiris therapeutics
xconomy.com » Xconomy Boston - Nov 5, 2008
Roundup, Life Sciences, deals Rebecca Zacks wrote: Last week brought an interesting mix of theory and practice about the impact of the current economic climate on life sciences. —There was a flurry of news related to …
Also tagged: drugs, people, roundup, vc, boston, deals, startups, genentech, dyax, bessemer venture partners, life sciences, genzyme, biogen idec, fred hutchinson cancer research center, cephalon, elan, tysabri, fred baron, boston blog main, national blog main, vertex pharmaceuticals, third rock ventures, acusphere, telaprevir, frazier healthcare ventures, fidelity biosciences, novartis option fund, alnara pharmaceuticals, azimuth opportunity, lauren silverman, bcm technologies, neuroventures capital, envivo pharmaceuticals, cogene ventures, ra capital management, peter kolchinsky, osiris therapeutics
businessweek.com » BusinessWeek Online -- Eye on Asia - Nov 3, 2008
With the cost of manufacturing in China going up and companies stung by an endless series of Made-in-China scandals, lots of corporate executives talk about a China-plus-one strategy. Yes, you can do a lot of your …